Navigation Links
AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing

RANCHO CORDOVA, Calif., Jan. 25, 2012 /PRNewswire/ -- AMPAC Fine Chemicals LLC (AFC), a wholly owned subsidiary of American Pacific Corporation (Nasdaq: APFC), announced today that is has been granted Registration as a Manufacturer of Controlled Substances from the U.S. Drug Enforcement Agency (DEA).

AFC has been involved in the development of Schedule II Controlled Substances since 2008 under a Researcher's License from the DEA.  Recent facilities upgrades have expanded AFC's capabilities to include commercial scale manufacturing of Schedule II controlled substances.  This manufacturing is conducted within a high security area of AFC's Rancho Cordova, California, facilities, which are located within a Department of Defense-regulated campus. 

"AFC's upgraded controlled substance facility offers a state-of-the-art, remotely operated process plant which can safely run hydrogenations and hazardous chemical processes, while containing reactants and products with Operator Exposure Limit as low as 0.5 micrograms per cubic meter. The recent upgrades satisfy DEA requirements for producing Schedule II intermediates and active pharmaceutical ingredients under current Good Manufacturing Practices (cGMP)," stated Larry Zeagler, Executive Director of Product Management for AFC.

"We are pleased to add controlled substance commercial manufacturing to the value proposition that we bring to our customers.  This major milestone enhances our position as a fine chemical supplier with world-class cGMP manufacturing capabilities in the United States," stated Aslam Malik, President of AFC.

AFC's entry into the field of controlled substances is enabled by a commercial arrangement with a large pharmaceutical company. These developments position AFC for significant growth in the controlled substances area.

AFC is a U.S.-based company with demonstrated capabilities in process development, scale-up, and cGMP-compliant commercial production of active pharmaceutical ingredients (API's) and registered intermediates for pharmaceutical and biotechnology customers. Its specially engineered facilities and experienced staff allow AFC to safely produce highly energetic compounds at commercial scale. In addition, AFC's other technology platforms include production of highly potent compounds, continuous processes and industrial-scale chromatographic separation using simulated moving bed chromatography (SMB).  AFC's operations are located in Rancho Cordova, CA, and in La Porte, Texas.  Additional information about us can be obtained by visiting our web site at

American Pacific Corporation (AMPAC) is a leading custom manufacturer of fine chemicals, specialty chemicals and propulsion products within its focused markets. We supply active pharmaceutical ingredients and advanced intermediates to the pharmaceutical industry. For the aerospace and defense industry we provide specialty chemicals used in solid rocket motors for space launch and military missiles. AMPAC also designs and manufactures liquid propulsion systems, valves and structures for space and missile defense applications. We produce clean agent chemicals for the fire protection industry, as well as electro-chemical equipment for the water treatment industry. Our products are designed to meet customer specifications and often must meet certain governmental and regulatory approvals. Additional information about us can be obtained by visiting our web site at

Statements contained in this press release that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including without limitation statements regarding anticipated benefits and outcomes of the Registration of AFC as a Manufacturer of Controlled Substances by the DEA. The inclusion of forward-looking statements should not be regarded as a representation by American Pacific Corporation and its affiliates (collectively, "American Pacific") that any of American Pacific's expectations will be achieved.  Actual results may differ materially from future results or outcomes expressed or implied by forward-looking statements set forth in this press release due to risks, uncertainties and other important factors inherent in American Pacific's business.  Factors that might cause actual results to differ include, but are not limited to, those included in the "Risk Factors" section of the Form 10-K for the fiscal year ended September 30, 2011, filed by American Pacific Corporation with the U.S. Securities and Exchange Commission.  Readers of this press release are referred to the filings of American Pacific Corporation with the U.S. Securities and Exchange Commission  or further discussion of these and other factors that could affect future results. The forward-looking statements contained in this press release are made as of the date hereof and American Pacific assumes no obligation to update for actual results or to update the reasons why actual results could differ materially from those projected in the forward-looking statements, except as required by law.  Technical Contact:


William DuBay, Ph.D., Vice President,

Technology and Business Development 


AMPAC Fine Chemicals 


+1 (800) 311-9668

+1 (916) 357-6880 


 Investor Contact:


Deanna Riccardi 


American Pacific Corporation 


+1 (702) 735-2200

SOURCE American Pacific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AMPAC Fine Chemicals Names Terry Vollrath Vice President of Operations
2. AMPAC Fine Chemicals Adds New Capabilities for Clinical Programs
3. Ampac Fine Chemicals President Aslam Malik Joins SOCMAs Board of Governors; Industry Veteran Adds Significant Experience to Board
4. AMPAC Fine Chemicals Partners With Inabata & Co., Ltd. of Japan
5. AMPAC Fine Chemicals Receives Prestigious Award at Californias Annual Statewide Environmental Summit
6. The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
7. European Fine Chemicals Group Ratifies FDAs Proposed Generic Drug User Fees Act (GDUFA)
8. Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
9. New ionator EXP(TM) and ionator HOM(TM) Kill Swine Flu Without Use of Chemicals
10. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
11. Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey
Post Your Comments:
(Date:11/25/2015)... announced the issue of United States patent No. 9,192,509  entitled: " Methods ... the company,s AVACEN 100 dry heat therapy medical device and specific methods of use, referred to ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
(Date:11/25/2015)... , Nov. 25, 2015  Mindray ... (NYSE: MR ), a leading ... devices worldwide, today announced that it ... meeting of shareholders at the Company,s Hong ... Century, 193 Prince Edward West Road, Mongkok ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
(Date:11/25/2015)... ... ... Beddit® has launched a new Android app for use with ... more intuitive SleepScore™ that rates sleep quality on a 100-point scale and makes it ... a proprietary algorithm. Beddit analyzes the data to provide an easy to understand scientific ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... D.C. (PRWEB) , ... November 25, 2015 , ... Today, ... fatalities on our nation’s roadways has dropped below 10,000 for the first time since ... 10,076 in 2013. , According to data released by the National Highway Traffic Safety ...
Breaking Medicine News(10 mins):